Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:

NCT ID: NCT05105412 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphomas (PTCL)

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Start date: October 31, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single country multi-center, open-label phase Ib/II single-arm study in relapsed or refractory PTCL patients. Patients will be treated with the combination of lenalidomide and gemcitabine until disease progression, intolerable toxicity, or patient withdrawal.

NCT ID: NCT05083208 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Start date: February 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.

NCT ID: NCT05079282 Recruiting - Clinical trials for Relapsed or Refractory T Cell Lymphoma

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Start date: December 10, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

NCT ID: NCT05075460 Recruiting - T-cell Lymphoma Clinical Trials

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Start date: October 1, 2021
Phase: Phase 3
Study type: Interventional

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

NCT ID: NCT05058755 Completed - Clinical trials for Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

Start date: September 17, 2021
Phase: N/A
Study type: Interventional

Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete remission rate of was low. Some anti-PD-1 antibody based regimen showed higher and deeper response in NKTCL patients.

NCT ID: NCT05010005 Active, not recruiting - Clinical trials for T-cell Large Granular Lymphocyte Leukemia

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.

NCT ID: NCT05006664 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Start date: October 2021
Phase: Phase 2
Study type: Interventional

A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)

NCT ID: NCT04984837 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Study of Lacutamab in Peripheral T-cell Lymphoma

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL). The design is non comparative meaning that non comparison between arms will be performed as the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1).

NCT ID: NCT04922567 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)

NCT ID: NCT04880746 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

Start date: October 17, 2020
Phase: Phase 3
Study type: Interventional

This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.